BTK and myeloid sarcoma: Furthermore, as new therapies such as Bruton tyrosine kinase (BTK) inhibitors specifically target MCs including brain-resident microglia and blood-derived monocytes, a better understanding of MC biology will be critical for the development of new interventional therapies in MS [30].